Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

Subjects:

Supplementary file 1_Intercropping of short- and tall-stature maize decreases lodging risk without yield penalty at high planting density.docx by Jianhong Ren (2186293)

“…Compared with IND, IHD did not significantly improve the population yield. The upper leaf area of intercropped XY was greater than sole stand, leading to increased interception of photosynthetically active radiation (PAR). …”

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Overview of the WeARTolerance program. by Ana Beato (20489933)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Structural equation models raw data. by K. Kanoho Hosoda (19929050)

Subjects:

Summary of sample descriptive statistics. by K. Kanoho Hosoda (19929050)

Subjects:

Characteristics of census tracts that are projected to have high (groups: 250-399 and 400+) and low (groups: 50-99 and 100-249) MHC utilization for COVID-19 vaccination before Marc... by Fatih Gezer (21485468)

Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3. by Anneli Peolsson (7867601)

Subjects: